Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Prodrug-activating systems in suicide gene therapy
Caroline J. Springer, Ion Niculescu-Duvaz
Caroline J. Springer, Ion Niculescu-Duvaz
Published May 1, 2000
Citation Information: J Clin Invest. 2000;105(9):1161-1167. https://doi.org/10.1172/JCI10001.
View: Text | PDF
Perspective

Prodrug-activating systems in suicide gene therapy

  • Text
  • PDF
Abstract

Authors

Caroline J. Springer, Ion Niculescu-Duvaz

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Self immolation of prodrug1 to yield the chemotherapeutic drug doxorubic...
Self immolation of prodrug1 to yield the chemotherapeutic drug doxorubicin. The doxorubicin prodrug (1) is cleaved by carboxypeptidase G2 (CPG2), releasing the glutamic acid (3) and an unstable intermediate (2). The latter undergoes a spontaneous 1,6 elimination, extruding doxorubicin (4), a quinone imine (5), and carbon dioxide. This scheme can be readily modified to allow the production of structurally similar drugs, such as daunorubicin.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts